×

G1 Therapeutics to Present New Data on CDK4/6 Inhibitor G1T28 at the 2015 American Society of Clinical Oncology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., May 13, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, announced today that new data on its lead compound G1T28 will be presented in two posters at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 29 - June 2 at McCormick Place in Chicago.

Details of the poster presentations are as follows:

Title: First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.
Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Date and time: Saturday, May 30, 8 – 11:30 a.m.
Location: S Hall A
Abstract: #2527
Presenting author: Rajesh Malik, G1 Therapeutics, Inc.

Title: Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression.
Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Date and time: Saturday, May 30, 8 – 11:30 a.m.
Location: S Hall A
Abstract: #2529
Presenting author: Patrick J. Roberts, G1 Therapeutics, Inc.

Abstracts for each presentation and additional information on the meeting can be found on the ASCO web site: http://am.asco.org/.

About G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a privately held clinical-stage pharmaceutical company based in Research Triangle Park, NC that focuses on the discovery and development of novel small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class drug candidates and best-in-class compounds that address two markets: CDK4/6 antineoplastics and protection of the bone marrow and immune system from damage by chemotherapy (chemoprotection). The company's lead program, G1T28, is a highly potent and selective CDK4/6 inhibitor that is currently being evaluated in Phase 1 clinical trials.

Visit www.g1therapeutics.com for more information.

CONTACT: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 mvelleca@g1therapeutics.com Media: Laura Bagby 6 Degrees Communications 312-448-8098 lbagby@6degreespr.com

Source: G1 Therapeutics